Patents and Postapproval Batch Testing - Can postapproval FDA filings immunize pharma companies from patent lawsuits? - BioPharm International

ADVERTISEMENT

Patents and Postapproval Batch Testing
Can postapproval FDA filings immunize pharma companies from patent lawsuits?


BioPharm International
Volume 25, Issue 12, pp. 55-56

REFERENCES

1. Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 669-71 (1990).

2. 35 U.S.C. 271(e)(1) (2012).

3. 659 F.3d 1057, 1060, 1070 (Fed. Cir. 2011).

4. Ibid. at 1060.

5. Ibid. at 1070-72.

6. Ibid. at 1070.

7. 686 F.3d 1348 (Fed. Cir. 2012).

8. Ibid. at 1351.

9. Ibid. at 1353.

10. Ibid. at 1352-53.

11. Ibid. at 1354-55.

12. Ibid. at 1361-76.

13. Ibid. at 1357-58.

14. Petition for a Writ of Certiorari at i., GlaxoSmithKline v. Classen Immunotherapies, Inc., No. 11-1078 (U.S. Feb. 28, 2012).

15. Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193, 206-07 (2005); Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Guilty Plea to Importing Illegal Cancer Drugs
August 15, 2014
Amgen Recalls Aranesp Prefilled Syringes
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here